V. 10. What We Measure and What It Means

There is no "normal" microbiome result, so this chapter separates the clinically useful targeted markers (calprotectin, H. pylori, SIBO) from full 16S/shotgun portraits and overpromising home tests — and shows when testing is actually worth it.

Over the past 5 years, so many microbiome tests have appeared on the market that it's hard to navigate which is scientific, which is marketing, and which has clinical value. This chapter sorts that out — what we can measure about the microbiome today, what it's good for, and what it isn't.

The topic matters more than it first appears. A test ordered at the wrong time isn't just wasted money — a misleading result can push you into unwarranted attempts while drawing attention away from the real diagnosis. A test ordered at the right time can save months of guesswork.

Why there's no "normal" microbiome result

The gut microbiome of healthy people shows far more variation than their blood count or blood sugar. Two healthy adults can share less than 50% of their gut bacteria at the species level — both healthy, yet with very different microbiomes. [541]

This has two important consequences. One: a reference value (a "normal range") isn't interpretable the way it is for, say, TSH. Two: the functional state may matter more than the taxonomic (the estimated frequency of bacterial occurrence). If two people's microbiomes differ taxonomically but both produce equal butyrate^[G] and maintain gut barrier function equally, both are clinically "fine."

16S rRNA sequencing

This is the most common and cheapest method. A region of the bacterial 16S rRNA gene (V3-V4 most often) is sequenced, and the sequences identify the bacteria present.

Good for: taxonomic overview at genus or higher level, alpha/beta-diversity computation, population-level comparison. Most commercial home tests use this.

Not good for: species- and strain-level identification (limited); doesn't detect viruses, fungi, or archaea (only bacteria); functional information (what the microbes actually do) only indirectly, and the algorithm used applies approximations.

The 16S is a list — it says nothing about what the listed bacteria actually produce, how they respond to diet, what relational network they form, or how stable they are.

Shotgun metagenomics

Here all DNA is sequenced, not just one gene. More expensive but far more informative.

Good for: species- and often strain-level identification, antimicrobial resistance (AMR) gene detection, functional gene listing (e.g., butyrate-production pathways, mucin-degrading enzymes), and detecting viruses and fungi.

Not good for: by itself it's still only potential — a gene's presence doesn't mean it's expressed. Functional activity requires metatranscriptomics (RNA) or metabolomics, rarely available clinically. And it works with a huge volume of data evaluated by software, with all the difficulties that entails.

Why microbiome tests are unreliable: methodological pitfalls

The previous two sections showed what 16S and shotgun measure. But for clinical decision-making, we also need to know where the information can be lost — and it turns out, in many places. The methodological pitfalls fall into four levels: pre-analytical (before the sample reaches the lab), 16S-specific, shotgun-specific, and common to all methods.

Before the sample reaches the lab: pre-analytical issues

Stool is not a homogeneous substance. A simple swab sample reflects a random region of the colon, and its microbial composition can differ from what an adjacent sample would yield. Scientific protocols compensate for this with homogenization (mixing the full sample and then aliquoting); most home tests provide no guidance on this.

Storage time and temperature also matter: at room temperature a measurable microbiome shift begins within hours (sensitive anaerobes die off, oxygen-tolerant species become over-represented). Frozen vs. fresh samples also yield different results.

And here is a conceptual nuance that already appeared in chapter 1, but is particularly important in the testing context: dysbiosis is not a deviation from some universal "ideal" microbiome. A healthy adult's microbiome can differ substantially from another's by sex, age, diet, lifestyle, and genetic background — and still sit in a stable, functional equilibrium. So when a test flags "dysbiosis," it really only says: this sample differs from the reference population the test uses. Whether that means anything for your health is a separate question.

16S-specific pitfalls

16S sequencing has five well-documented weaknesses.

1. Reagent contamination: DNA can come not only from the submitted sample but also from the lab equipment and reagents themselves, and at low sample biomass this contamination signal can exceed the actual sample signal. [548]
2. The low-biomass effect: detection of rare bacteria is often indistinguishable from the contamination background. [549]
3. "Universal" primers are not universal: the choice of the 16S gene's V-region (V1-V2 vs. V3-V4 vs. V4 etc.) yields different bacterial profiles on the same sample — a species detectable with one primer set may be invisible to another.
4. Inter-lab variability: the same sample analyzed by different labs with different kits and bioinformatics gives substantially different results — meaning the data often depends on the method, not the sample. [16]
5. The compositional data pitfall: 16S gives relative proportions (what's present relative to others), not absolute quantities. A species "increase" may actually be the mirror image of another species' decrease. [18]

Shotgun-specific pitfalls

Shotgun metagenomics is more informative, but its pitfalls are also more serious.

1. The DNA extraction method dominates everything: Costea et al. 2017 Nature Biotechnology — the same stool sample processed by 21 different methods produced 21 different microbial profiles. [19] This means two labs with different extraction protocols won't produce concordant results even if the sample physically came from the same patient on the same day.
2. Host DNA dominance: if the sample contains lots of human DNA, it "soaks up" sequencer bandwidth, and rarer microbes go undetected. Human-DNA depletion steps to correct for this introduce their own biases. [476]
3. The bioinformatic pipeline choice: the CAMI consortium (Critical Assessment of Metagenome Interpretation) international benchmarks show that pipeline choice influences the outcome more than the actual biological difference between samples. [22]
4. Finally, systemic bias at every level: McLaren et al. 2019 eLife — microbiome measurements consistently show method-dependent biases that make data simply not comparable across protocols. [21]

A shared problem: method-mediated false discoveries

One instructive case of the 2010s was the hypothesized "in utero microbiome": early studies detected bacterial DNA in placenta and amniotic fluid, generating major scientific excitement. Later reanalyses with stricter controls showed that much of the signal came from laboratory background contamination, not a true fetal microbiome. [558] This wasn't an isolated mistake but a system-wide warning.

Exactly these experiences led to STORMS (Strengthening The Organization and Reporting of Microbiome Studies) reporting standards and RIDE-style quality frameworks. [306] Without them, microbiome publications can easily mislead, and clinically actionable results often deliver less than the publications themselves claim.

The clinical takeaway

From all the methodological pitfalls follows one practical message.

1. We know we are measuring — but we don't always know precisely what we're measuring.
2. We don't necessarily know what it does in the body, that thing we measured.
3. We can't always say whether it's "a lot" or "a little" for a given person in a given state.

Health-sustaining equilibrium can be achieved with many compositions — meaning you can have a "flawless" report while you feel unwell, and a "terrible" report while you function perfectly.

This is why one of the oldest rules of clinical practice applies here too: we don't treat the lab result — we treat the patient. A microbiome test is therefore a tracking tool (same sampling + lab + algorithm), not a standalone diagnostic decision-maker.

The home microbiome test market

More than 20 commercial home tests are available, priced ~$80–1,100 in most EU markets. The typical offer: "send in a stool sample, we 16S-sequence it, and you'll get personalized lifestyle and nutrition recommendations."

Market offerings fall into three tiers by scientific defensibility:

Defensible: tests that return 16S or shotgun data in accessible raw form (FASTQ file) and don't promise specific disease diagnoses. The user (or treating physician) extracts what science actually allows. Example: American Gut Project (research-based, low cost).

Overpromising but not harmful: "gut-friendly diet recommendations based on your microbiome" — the problem isn't the data, it's the recommendation-generation mechanism. Current knowledge can't reliably derive individual-specific diets from a 16S result. The recommendations are likely as generic (more fiber, fermented foods) as those everyone gets in chapter 4 — just pricier and "personalized." Example: several European and American home tests.

Scientifically problematic: "autism microbiota profile," "depression microbiota signature," "cancer risk from microbiome." These promise diagnostic certainty in the and zones of chapter 3's evidence map — certainty science doesn't yet provide. Here we recommend caution.

Markers used in clinical practice

The following tests are part of clinical practice and support real decision-making. You can request these from your treating physician when symptoms warrant.

Fecal calprotectin

Fecal calprotectin is a protein from neutrophil granulocytes — its level reflects gut mucosal inflammation. The most useful decision it supports: differentiating IBD flare vs. IBS.

• < 50 µg/g — inflammation unlikely (IBS-like picture)
• 50–250 µg/g — equivocal, repeat or supplementary investigation indicated
• > 250 µg/g — active inflammation (colonoscopy warranted)

Calprotectin is also used in supervised IBD patients to track activity: stable low values during remission signal treatment success. [545]

Fecal and serum zonulin — disputed

Zonulin regulates tight junctions^[G] of the gut barrier and is a popular marker in "leaky gut" diagnosis. Problems: most commercial ELISA kits don't actually measure zonulin — they cross-react with other proteins (complement C3, pre-haptoglobin-2). [546] The "high zonulin = leaky gut" link isn't well validated clinically. Clinical recommendation: treat with caution; do not build a stand-alone diagnosis on it.

SIBO breath tests (lactulose, glucose)

Small intestinal bacterial overgrowth (SIBO) has traditionally been diagnosed via duodenal aspirate culture, but breath tests (measuring H₂ and CH₄ after oral lactulose or glucose) are more accessible. Limitations: the lactulose breath test is sensitive but false-positives are common; glucose is more specific but less sensitive. The 2020 North American Consensus recommends the glucose breath test as preferred. [547]

The clinical significance of SIBO is likely in IBS-D and rosacea (see chapter 3); rifaximin eradication can improve symptoms in a subgroup. At the same time, both the mechanism of the whole condition and the experimental attempts to cure it show that science often still focuses on bowel segments rather than on a holistic restoration of digestion. The growing use of oral FMT preparations substantially nuances the very existence of SIBO as an entity.

Fecal Helicobacter pylori antigen

Simple, cheap, non-invasive test for H. pylori infection diagnosis and post-eradication follow-up. Indication: dyspeptic symptoms, gastric ulcer history, or family history of gastric cancer. The test is sensitive and specific (~95% both ways) and cheaper than breath tests.

Other useful stool tests

• Fecal occult blood (FIT) — colorectal cancer screening, recommended from age 50
• Fecal elastase — exocrine pancreatic insufficiency
• Stool pH and reducing sugars — for lactose/carbohydrate malabsorption

When does microbiome testing make sense?

Four common profiles — with different recommendations:

"I'm healthy and just curious": a home 16S test is acceptable as curiosity. Realistic expectation: interesting data but little for clinical decisions. Cheaper and more informative: a food diary + executing chapter 4.

"I have symptoms (bloating, alternating bowel)": medical workup first, with symptom-matched targeted tests (calprotectin, H. pylori, SIBO breath test). Microbiome testing only after, if your treating physician deems it relevant.

"I'm a diagnosed IBD/IBS/celiac patient": calprotectin is part of care. A general microbiome test does not routinely help with decisions.

"I have a specific concern (e.g., family CRC, suspected family IBD)": colonoscopy screening and genetic testing — that's the main path, not a microbiome test.

How to interpret a result

The same result handed to two people yields two kinds of value:

Lay reader: three questions worth answering:

1. Are there red flags in the result (e.g., known pathogen like Salmonella, C. difficile, Yersinia)?
2. Is alpha-diversity extremely low?
3. Do recommended lifestyle steps match chapter 4? If yes, follow; if drastic "detox" or "eliminate this food group" recommendations appear, be suspicious.

Clinician reader: look at functional aspects:

1. presence of butyrate producers (Faecalibacterium prausnitzii^[G], Roseburia, Eubacterium rectale),
2. Akkermansia muciniphila^[G] abundance,
3. Enterobacteriaceae expansion (inflammatory marker).

Interpret the taxonomic list diagnostically only when clinical context supports it.

When the Microbiome Is Not Responsible — Differential Diagnosis

A common but dangerous pitfall: someone with GI symptoms who has read a few microbiome articles tends to attribute every problem to "dysbiosis." Clinical reality is more nuanced — many GI symptoms have the microbiome as at most a secondary player, and some conditions require standalone treatment.

Symptoms where the microbiome is generally not the primary cause

Acute abdominal pain + fever or guarding: appendicitis, cholecystitis, diverticulitis, perforation — surgical or emergency workup, not microbiome analysis.

New onset or progressive dysphagia: esophageal strictures, motility disorder, occasionally tumor — endoscopy and manometry.

Acute bloody stool + hemodynamic instability: severe bleeding (diverticulosis, AVM, lower GI tumor) — emergency care.

Persistent epigastric pain after meals: gallstones, pancreatic problem, peptic ulcer — gastroscopy, abdominal ultrasound.

New unintentional weight loss >5% over 6 months: malignancy rule-out is mandatory — tumor screening.

Symptoms where the microbiome is secondary (treatable but not standalone)

Celiac disease: autoimmune, gluten-trigger-requiring — gluten-free diet is primary, microbiome restoration is adjunct.

Lactose/fructose intolerance: enzyme deficiency or absorption problem — diet-based, microbiome-directed step is secondary.

Endocrine diseases (hyperthyroidism, Addison's, diabetes): metabolic, treating the underlying disease is primary.

Mental illness with GI manifestation: depression, anxiety-caused functional symptoms — psychological treatment is central.

Symptoms where the microbiome likely plays a primary role

IBS (per Rome-IV criteria, organic causes excluded): functional picture, the microbiome-stressor-axis combination is a meaningful target (see chapters 3, 11).

Antibiotic-related persistent symptoms (>4 weeks): microbiome disruption is likely, regeneration can be guided (chapter 7).

Recurrent C. difficile infection: FMT is clinical indication (chapter 11).

Non-specific "fatigue + gut + skin" constellation without anatomic alteration: microbiome-directed lifestyle levers (chapters 4–5) give the best ratio.

Sample-Interpretation Example

Suppose a 32-year-old woman with IBS diagnosis does a home microbiome test, and the result shows her alpha-diversity in the bottom 25%, Akkermansia muciniphila undetectable, and Faecalibacterium prausnitzii relative abundance at 1.2% (average 3–7%).

A responsible clinical interpretation:

1. What does this test not say? — it doesn't give a diagnosis, doesn't say whether IBS is the cause or consequence of the microbiome, doesn't say which bacterium must be "replaced"
2. What does it suggest? — low butyrate-producer abundance is consistent with IBS-D; consistent with chapter 3's evidence map, but not pathognomonic
3. What step is warranted? — strengthening the basics (chapter 4 fiber intake, fermented) + 4–8 week subtype-specific probiotic trial (e.g. B. infantis 35624) + clinical dietitian for FODMAP protocol
4. What is not warranted? — expensive targeted "Akkermansia-supplement" product (currently AKK probiotic still in clinical trials; commercial product reliability is questionable)

An irresponsible interpretation: "your Akkermansia is 0, therefore you must order a polyphenol package, and you have IBS because of your microbiome" — that's over-interpretation, and doesn't help the patient.

What you can do tomorrow

1. If you have symptoms: see your GP. Ask whether stool calprotectin, H. pylori antigen, FIT, or SIBO breath test is warranted. Consider microbiome testing only afterward if your specialist finds it relevant.
2. If you're healthy: don't pay for a home test; instead implement chapters 4–5. If you still want to test, choose one that returns raw data.
3. If you're a supervised IBD/IBS patient: follow the markers your treating physician recommends. Don't add a general microbiome test without discussing it with them.
4. If you're in CRC screening age (45+ EU; 50+ local): FIT or colonoscopy is the main path — not replaceable by a microbiome test.

What's next

Chapter 11 covers the therapeutic toolbox: once we know what we measured and what it means, what can actually be done? Strain-specific probiotic selection, prebiotic choice, synbiotics, FMT indications, and next-generation tools.

References

[16] Sinha R, Abu-Ali G, Vogtmann E et al. Assessment of Variation in Microbial Community Amplicon Sequencing by the Microbiome Quality Control (MBQC) Project Consortium. Nature Biotechnology. 2017. Link

The Microbiome Quality Control (MBQC) baseline study assessed taxonomic profiling variability across 15 laboratories and 9 bioinformatics protocols using blinded stool, chemostat and artificial community specimens. Variability depended most on biospecimen type and origin, followed by DNA extraction, sample handling environment and bioinformatics pipeline. Artificial community analyses revealed quantitative differences in extraction efficiency and bioinformatic classification. The findings highlight the need for standardisation to enable meta-analysis of population-scale microbiome studies.

[18] Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome datasets are compositional: and this is not optional. Front Microbiol. 2017. Link

Microbiome datasets generated by high-throughput sequencing of 16S rRNA amplicons, metagenomes or metatranscriptomes are inherently compositional because the instrument imposes an arbitrary total. The review explains the pathologies that arise when compositional data are analysed with non-compositional methods and provides guidance for applying compositional data analysis throughout microbiome study workflows. The compositional framework is presented as essential, not optional, for valid inference.

[19] Costea PI, Zeller G, Sunagawa S et al. Towards Standards for Human Fecal Sample Processing in Metagenomic Studies. Nature Biotechnology. 2017. Link

21 representative DNA extraction protocols were tested on identical faecal samples and compared with library preparation and storage effects against biological within-individual variation. DNA extraction had the largest technical effect on metagenomic outcomes. Protocols were ranked by DNA quantity, quality, and biases in community diversity and Gram-positive/Gram-negative ratio. The authors recommend a standardised, transferable DNA extraction method validated using a mock community of known composition for human faecal metagenomic studies.

[21] McLaren MR, Willis AD, Callahan BJ. Consistent and Correctable Bias in Metagenomic Sequencing Experiments. eLife. 2019. Link

Marker-gene and metagenomic sequencing measurements are systematically biased toward detecting certain taxa over others, making taxon abundances generated by different protocols quantitatively incomparable and prone to spurious biological conclusions. The authors propose a mathematical model of experimental bias based on real-experiment properties and validate it with 16S rRNA and shotgun metagenomics data from defined bacterial communities. The model fits experimental data better than previous, more complex frameworks and offers a path to correcting bias.

[22] Sczyrba A, Hofmann P, Belmann P et al. Critical Assessment of Metagenome Interpretation -- A Benchmark of Metagenomics Software. Nature Methods. 2017. Link

The Critical Assessment of Metagenome Interpretation (CAMI) challenge benchmarked metagenomics software using highly complex realistic datasets from ~700 newly sequenced microorganisms and ~600 novel viruses and plasmids. Assembly and binning performed well for species represented by individual genomes but were substantially degraded by closely related strains. Taxonomic profiling and binning were proficient at high taxonomic ranks with a marked drop below family level. Parameter settings strongly affected performance, underscoring the importance of reproducibility. CAMI provides a roadmap for software selection.

[306] Mirzayi C, Renson A, Genomic Standards Consortium et al. Reporting Guidelines for Human Microbiome Research: The STORMS Checklist. Nature Medicine. 2021. Link

This methodological consensus from multidisciplinary microbiome researchers adapted observational and genetic epidemiology reporting guidelines into the Strengthening The Organization and Reporting of Microbiome Studies (STORMS) tool. STORMS is a 17-item checklist organized into six sections matching typical publication structure, with new elements for laboratory, bioinformatics and statistical analyses specific to culture-independent microbiome studies. The findings provide a standardized reporting framework facilitating manuscript preparation, peer review, reader comprehension and comparative analysis of microbiome studies.

[476] Marotz CA, Sanders JG, Zuniga C et al. Improving Saliva Shotgun Metagenomics by Chemical Host DNA Depletion. Microbiome. 2018. Link

To enable shotgun metagenomic sequencing of host-dominated oral samples, three commercial host-depletion kits, size filtration, and a novel osmotic-lysis + propidium-monoazide method (lyPMA) were compared in human saliva. lyPMA was the most efficient method, reducing host-aligned reads from 89,29 ± 0,03% in untreated samples to 8,53 ± 0,10%. Furthermore, lyPMA-treated samples showed the lowest taxonomic bias compared with untreated controls. The method is recommended for microbial-DNA enrichment from host-rich oral samples in metagenomic studies.

[541] Knight R, Vrbanac A, Taylor BC et al. Best practices for analysing microbiomes. Nat Rev Microbiol. 2018. Link

Best-practice review for microbiome study design, molecular technology choice, data analysis and multi-omics integration. The authors recommend exact sequence variants (ASVs) over OTU-based analyses; discuss methods for combining metagenomic and metabolomic data; and address compositional data analysis, where progress has been particularly rapid. Classical concerns of experimental design and research reproducibility remain critical. Keeping these in mind allows deeper insight from microbiome datasets across human and environmental contexts.

[542] McDonald D, Hyde E, Debelius JW et al. American Gut: an Open Platform for Citizen Science Microbiome Research. mSystems. 2018. Link

The American Gut Project compared >10 000 citizen-scientist stool samples from the US, UK and Australia with environmental samples using Earth Microbiome Project standardized protocols. Human stool microbiomes showed unexpectedly wide beta-diversity compared with environmental samples. Open data integration enabled discovery of new molecules and untargeted-metabolomic associations with diverse plant intake (a stronger predictor than reductive categorical variables like veganism). The work demonstrates feasibility of mail-shipped, self-collected microbiome samples for reproducing known and revealing new associations, including psychiatric illness links and individual perturbations such as surgery.

[543] Allaband C, McDonald D, Vázquez-Baeza Y et al. Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol. 2019. Link

Clinically-oriented review of microbiome content, intersubject and intrasubject variability, study-design considerations and confounders, and laboratory and computational methods for reading microbiota, gene products and metabolites. Common pitfalls for clinicians are highlighted: the misconception that an individual's microbiome is stable; that diet induces rapid changes large relative to interindividual differences; that all people share a core stool microbiome; and that all lab/computational pipelines yield equivalent results. Understanding current limits and future promise is essential for translation to routine clinical care.

[545] Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol. 2016. Link

IBD and IBS share many clinical symptoms, so accurate diagnosis is essential since IBD therapy is evolving rapidly while IBS is largely managed symptomatically. Clinical assessment combined with imaging and endoscopy has long been the diagnostic mainstay. Over the past decade fecal biomarkers of GI inflammation — chiefly calprotectin, a neutrophil cytosolic protein — have entered routine use. Calprotectin enables objective assessment of disease activity and treatment response in the chronic remitting-relapsing IBD courses (Crohn's disease, ulcerative colitis).

[546] Scheffler L, Crane A, Heyne H et al. Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family. Front Endocrinol. 2018. Link

The authors show that the widely used commercial zonulin ELISA does not measure pre-haptoglobin-2 ('true' zonulin): mass spectrometry identified complement C3 and properdin (complement factor P) as the proteins recognized by the kit, not pre-HP2 — undermining the validity of zonulin data obtained with this assay as a barrier marker.

[547] Rezaie A, Buresi M, Lembo A et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. Am J Gastroenterol. 2017. Link

Pre-meeting survey questions across five domains (indications, preparation, performance, interpretation, knowledge gaps) were sent to 17 clinician-scientists; 10 attended a live meeting. Using an evidence-based approach, 28 statements were finalized and anonymously voted by the working group. Consensus was reached on 26 statements covering all five domains. These guidelines aim to standardize indications, methodology and interpretation of breath tests for carbohydrate maldigestion syndromes and small intestinal bacterial overgrowth (SIBO).

[548] Eisenhofer R, Minich JJ, Marotz C, Cooper A, Knight R, Weyrich LS. Contamination in Low Microbial Biomass Microbiome Studies: Issues and Recommendations. Trends Microbiol. 2019. Link

Next-generation sequencing in microbiome research enables high-sensitivity community surveys but also efficiently detects contaminant DNA and cross-contamination, especially in low-biomass samples. The authors review sources and impacts of contamination and identify key measures to mitigate it. They propose a minimum-criteria checklist, 'RIDE', to improve the validity of future low-microbial-biomass studies — covering reagent and instrument controls, internal contamination tracking, DNA dilution series and experimental positive controls.

[549] Karstens L, Asquith M, Davin S et al. Controlling for Contaminants in Low-Biomass 16S rRNA Gene Sequencing Experiments. mSystems. 2019. Link

Same dataset as ref-471: a mock community dilution series tested four computational decontamination methods (negative-control filtering, abundance filtering, Decontam, SourceTracker). Contaminant DNA proportion rose with decreasing biomass — 80,1% in the most diluted sample. The benchmark guides choice of bioinformatic contamination-removal pipelines, particularly for low-microbial-biomass samples where in silico methods have inherent limits.

[558] Kennedy KM, de Goffau MC, Perez-Muñoz ME et al. Questioning the fetal microbiome illustrates pitfalls of low-biomass microbial studies. Nature. 2023. Link

The authors evaluate recent studies claiming microbial colonization of human fetuses and the intrauterine environment from reproductive-biology, microbial-ecology, bioinformatic, immunological, clinical-microbiological and gnotobiological perspectives. They conclude that detected microbial signals are likely the result of contamination during sampling, DNA extraction or sequencing. The existence of live, replicating microbial populations in healthy fetal tissue is incompatible with established immunological, clinical-microbiological and germ-free-mammal-derivation principles. The fetal microbiome serves as a cautionary example of low-biomass-sequencing pitfalls and the need for a trans-disciplinary approach.

[559] Drossman DA, Hasler WL. Rome IV — Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016. Link

Drossman and Hasler's 2016 Gastroenterology paper introduces Rome IV — the major revision of the Rome diagnostic criteria for Functional GI Disorders, now reframed as 'Disorders of Gut-Brain Interaction'. The new framework integrates biopsychosocial, microbiota-gut-brain-axis, and visceral hypersensitivity concepts, replacing the older 'functional' label with a mechanism-aware terminology. The paper outlines updates to the diagnostic criteria for IBS, functional dyspepsia, functional constipation/diarrhoea, abdominal pain, and other disorders, with revised symptom frequency thresholds and subtype definitions. Rome IV is the operative reference for functional GI/DGBI diagnosis worldwide, cited extensively in clinical practice, research and microbiome-IBS literature.